In the present study, we attempted to evaluate the feasibility of PTE chemotherapy for previously treated advanced HER2-positive breast cancer and to analyze QOL and biomarkers such as sHER levels, PIK3CA gene mutation status and circulating Tregs. This evidence concerns the gene ERBB2 and breast carcinoma.